GlassScriptPhysician profile
Kyungran Gibson
NPI 1649897372
$5,715.30
in general payments reported to CMS, 2019-2025
37 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $304 · 2022: $1,459 · 2023: $1,391 · 2024: $1,278 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,940 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,940.01 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,135.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $948.86 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $710.27 | 2021-2025 | Entyvio, Gattex |
| Gilead Sciences, INC. | $433.00 | 2022-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $332.60 | 2024-2025 | Voquezna |
| Genzyme Corporation | $316.11 | 2022-2025 | |
| Daiichi Sankyo INC. | $274.06 | 2023-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $177.03 | 2022-2024 | Linzess |
| Pfizer INC. | $118.79 | 2024-2025 | |
| Lilly USA, LLC | $99.20 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $96.59 | 2022-2024 | Ocaliva |
| Celgene Corporation | $93.49 | 2022-2023 | Zeposia |
| Ardelyx, INC. | $93.18 | 2022-2025 | Ibsrela |
| Allergan, INC. | $83.17 | 2021 | |
| Qol Medical, LLC | $80.44 | 2023-2025 | Sucraid, Sucraid |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyungran Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.